BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Valanparambil, Rajesh M., Lai, Lilin, Johns, Margaret A., Davis-Gardner, Meredith, Linderman, Susanne L., McPherson, Tarrant Oliver, Chang, Andres, Akhtar, Akil, Gamarra, Estefany L. Bocangel, Matia, Hayley, McCook-Veal, Ashley A., Switchenko, Jeffrey, Nasti, Tahseen H., Green, Felicia, Saini, Manpreet, Wieland, Andreas, Pinsky, Benjamin A., Solis, Daniel, Dhodapkar, Madhav V., Carlisle, Jennifer, Ramalingam, Suresh, Ahmed, Rafi, Suthar, Mehul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663480/
https://www.ncbi.nlm.nih.gov/pubmed/37990024
http://dx.doi.org/10.1038/s41541-023-00779-8
Descripción
Sumario:This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.

Ejemplares similares